Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-7-20
pubmed:abstractText
In order for gene delivery to be clinically acceptable, a number of crucial developments need to be made to existing vectors. Significant advances have been made in the identification of novel platform vectors that possess modified tropism to the native vector, directing infectivity away from nontarget tissues such as the liver. In order to fully optimize these detargeted platform vectors, they need to be retargeted toward a chosen, defined site, which will be defined according to the disease studied. The successful transition of targeting peptides identified using in vitro screening protocols to an in vivo disease model may be compromized by the complexity of delivery into an intact biological system. To this end, peptides identified using in vivo biopanning may prove to be of greater clinical significance given that they were identified in the disease model of choice and so should translate more successfully to the intact preclinical model. Exploitation of the heterogeneity of the vascular endothelium using such an approach will go a long way toward improving the efficiency and achieving site-specific gene expression, with important clinical implications for the systemic application of gene delivery.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1543-1894
pubmed:author
pubmed:issnType
Print
pubmed:volume
108
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
395-413
pubmed:dateRevised
2006-4-21
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
In vivo biopanning: A methodological approach to identifying novel targeting ligands for delivery of biological agents to the vasculature.
pubmed:affiliation
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK.
pubmed:publicationType
Journal Article